Kardigan (KARD) news

Kardigan - Q2 net loss was $116.20 mln

Kardigan Inc. reported a net loss of $116.20 million for the second quarter of 2026, doubling its first-quarter loss of $56.1 million. The company attributes the increased loss to ongoing research and development costs associated with its pipeline of cardiovascular therapies. Kardigan, which…

Kardigan Inc: Jefferies initiates coverage with buy rating; target price $40

Kardigan Inc. (KARD) has recently drawn attention from Jefferies, which has initiated coverage of the biopharmaceutical company with a "Buy" rating and a target price of $40 per share. The stock closed at $22.00 on July 13, 2026, representing a market capitalization of approximately $1.97 billion…

Kardigan Inc: JP Morgan initiates coverage with overweight rating; target price $51

J.P. Morgan Chase & Co. (JPM) has initiated coverage on Kardigan, Inc. (KARD), a clinical-stage precision therapeutics company focused on developing treatments for cardiovascular diseases with no approved therapies. The firm assigned an "overweight" rating to KARD and set a target price of $51 per…

Kardigan shares open at $16.25 in Nasdaq debut vs $16 IPO price

Kardigan upsized IPO prices at $16/shr

Kardigan, a cardiovascular-focused biotechnology company, has priced its upsized initial public offering (IPO) at $16 per share, raising a total of $372.8 million . The company initially filed to offer 23.3 million shares at a range of $14 to $16 per share. With the final price set at the top of…